Registration for this event has closed.
About Payal Agrawal Divakaran
Payal is a Partner at .406 Ventures, where she co-leads the digital health investing practice. .406 Ventures is a Boston-based venture capital firm with $1.4B under management. Since its founding in 2005, .406 Ventures has never wavered from its strategy of investing in early-stage enterprise-focused startups in digital health, cybersecurity, and data & cloud. Every member of the firm has deep operating or investing experience in these segments.
.406’s world-class founders and digital health companies are transforming healthcare technology and care delivery. Payal’s portfolio includes AristaMD, Better Life Partners, Diana Health, Equip, Heartbeat Health, Laudio, Nomad Health, Redox, Wayspring, WelbeHealth, and Wellist.
Payal joined .406 after her time at Harvard Business School, where she co-founded a company called SpotRocket to help students discover high potential startups to work for. Prior to her entrepreneurial stint and also while in business school, Payal spent time in Corporate Development at Eventbrite.
Prior to HBS, Payal was an Associate at Spectrum Equity, a technology growth equity investor in Boston. She sourced and executed on deals in the software, information services, data/analytics, security, and internet spaces. Payal started her career pursuing technology investment banking at J.P. Morgan in NYC.
Payal received her MBA, with Distinction, from Harvard Business School and her BS in Electrical Engineering and minor in Management from MIT. She is a Boston native and Boston sports fan, and she and her husband, who is a physician at Brigham and Women’s Hospital, and two kids live in Brookline.
About Kathryn Taylor Reddy
Kathryn is a Principal at .406 Ventures, a Boston-based venture capital firm with $1.4B under management that invests in early-stage enterprise-focused startups in digital health, cybersecurity, and data & cloud. Kathryn joined .406 in 2021 and focuses on early-stage companies that offer systems, technologies, and services that support and improve clinical delivery. Her .406 portfolio includes Diana Health, On Belay, InStride, Lynx, ClosedLoop, Cortica, and Tausight.
Prior to joining .406, Kathryn was a Vice President at BPEA, where she executed direct investments for BPEA’s Strategic Healthcare fund, a $352M fund that invests in healthcare companies on behalf of Taft-Hartley plans and other institutional investors. As part of her role at BPEA, she worked closely with Taft-Hartley leaders to understand their healthcare challenges and sourced investments to address their needs. Prior to BPEA, she invested in healthcare technology and life sciences startups at Excel Venture Management. Kathryn also has experience working with large provider systems, health plans, and pharmaceutical companies. She worked as a project manager in corporate strategy at the Advisory Board and as an advisor to the Chief Medical Officer at Boston Medical Center’s HealthNet plan. Kathryn started her career in consulting at Putnam Associates, where she worked with top 20 pharmaceutical companies on product and portfolio strategies.
Kathryn is originally from Houston, TX. In her spare time, she enjoys exploring the Boston area with her husband and 1.5-year old son and traveling back home to Texas. She received a BA in quantitative economics and international relations from Tufts University and an MBA from Harvard Business School.